Latest from Bill of Health - Page 2

By Eiko I. Fried and Michiel van Elk
Much optimism has been expressed about the potential of psychedelics to treat mental health problems such as suicidal ideation, depression, and post-traumatic stress disorder. This optimism goes hand in hand with a notable increase in research publications, investments from pharmaceutical companies, patent filings, media exposure, as well

By David Herzberg
As a historian of psychoactive pharmaceuticals in the 20th century U.S., I see history rhyming in potentially dangerous ways in the current psychedelic boom. After decades of being associated with insanity, violence, and social disorder, psychedelics are now being embraced as potential wonder drugs. What appears to be a radical, 180-degree shift

By Patric Plesa
As interest in psychedelics research and popular psychedelics culture resurges, it is becoming progressively more difficult to discern facts from fantasy. As an academic with expertise in psychology, I too share in the growing enthusiasm for psychedelics research, especially toward therapeutic ends. But I believe a critical perspective, characterized by open science

By Caroline Hayes
The psychedelic renaissance is well underway, with hundreds of clinical trials currently looking into a plethora of different mental health conditions. I was a sub-investigator on a clinical trial researching a psychedelic study drug to treat depression, but I have since stepped back from psychedelic clinical trials due to personal ethical concerns

By Neşe Devenot
Since the 2022 publication of “Preparing for the Bursting of the Psychedelic Hype Bubble,” a JAMA Psychiatry Viewpoint by David Yaden and colleagues, a wave of scholarship and commentaries has emphasized the ethical importance of nuanced science communication about the still-nascent field of psychedelic medicine.

As the journalist Katie MacBride

By Vincent Joralemon
There is little consensus in defining “psychedelic.” Yet, research on and access to these substances hinges on what gets included in the “psychedelic” umbrella. It is time to talk about why we include (and exclude) particular drugs from this category.

Grants, Research, and Medical Codes
This matters because funding will flow from

By Adithi Iyer
The legal world is atwitter with the developing artificial intelligence (“AI”) copyright cage match between The New York Times and OpenAI. The Times filed its complaint in Manhattan Federal District Court on December 27 accusing OpenAI of unlawfully using its (copyrighted and paywalled) articles to train ChatGPT. OpenAI, in turn, published a

By Timothy Fish Hodgson, Roojin Habibi, and Alicia Ely Yamin
In developing the digital symposium, From Principles to Practice: Human Rights and Public Health Emergencies (which ran from October – December 2023), as editors we endeavored to get scholars, human rights advocates, judges, and policy makers to engage critically with the expert Principles and Guidelines

By Joelle Boxer
Tracy Droz Tragos’ new documentary, “Plan C,” follows the work of a grassroots organization dedicated to improving access to the abortion pill by mail in the U.S., while navigating an increasingly restrictive legal landscape.
There is no better time to hear the perspectives of these patients, providers, and activists. Just